Resona Asset Management Co. Ltd. Has $272.75 Million Stock Holdings in Eli Lilly and Company $LLY

Key Points

• Resona Asset Management trimmed its Eli Lilly stake by 3.9% in the fourth quarter, but still held 253,624 shares worth about $272.75 million, making LLY its 11th-largest position.
• Eli Lilly reported strong quarterly results, with EPS of $8.55 beating estimates and revenue of $19.80 billion topping forecasts, while sales rose 55.5% from a year earlier.
• The company also announced a quarterly dividend of $1.73 per share, and analysts remain broadly bullish, with a consensus rating of Moderate Buy and an average target price of $1,218.33.

Resona Asset Management Co. Ltd. decreased its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 3.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 253,624 shares of the company's stock after selling 10,241 shares during the period. Eli Lilly and Company makes up about 1.3% of Resona Asset Management Co. Ltd.'s portfolio, making the stock its 11th largest position. Resona Asset Management Co. Ltd.'s holdings in Eli Lilly and Company were worth $272,751,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of LLY. Maryland Capital Advisors Inc. acquired a new position in Eli Lilly and Company during the 4th quarter valued at about $25,000. Vermillion & White Wealth Management Group LLC boosted its stake in Eli Lilly and Company by 84.2% during the 3rd quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company's stock valued at $27,000 after purchasing an additional 16 shares during the last quarter. 10Elms LLP boosted its stake in Eli Lilly and Company by 33.3% during the 3rd quarter. 10Elms LLP now owns 40 shares of the company's stock valued at $31,000 after purchasing an additional 10 shares during the last quarter. E Fund Management Hong Kong Co. Ltd. boosted its stake in Eli Lilly and Company by 342.9% during the 4th quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company's stock valued at $32,000 after purchasing an additional 24 shares during the last quarter. Finally, Miller Global Investments LLC acquired a new position in Eli Lilly and Company during the 4th quarter valued at about $33,000. Institutional investors and hedge funds own 82.53% of the company's stock.

Eli Lilly and Company Trading Down 1.6%

Shares of LLY stock opened at $988.76 on Tuesday. The company has a 50 day moving average of $940.00 and a 200-day moving average of $999.39. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,133.95. The firm has a market cap of $931.15 billion, a P/E ratio of 35.12, a PEG ratio of 1.09 and a beta of 0.48.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The company had revenue of $19.80 billion during the quarter, compared to analyst estimates of $17.82 billion. During the same quarter last year, the business posted $3.34 EPS. Eli Lilly and Company's quarterly revenue was up 55.5% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Sell-side analysts anticipate that Eli Lilly and Company will post 35.82 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th will be given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date of this dividend is Friday, May 15th. Eli Lilly and Company's dividend payout ratio is currently 24.58%.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Investor enthusiasm remains supported by Eli Lilly’s powerful obesity and diabetes drug franchise, with articles highlighting surging Mounjaro/Zepbound demand and expectations for continued growth. Article Title
• Positive Sentiment: Recent business momentum is still very strong, with second-quarter-level commentary pointing to major sales growth and raised revenue expectations that reinforce the company’s long-term earnings power. Article Title
• Neutral Sentiment: Eli Lilly said it will participate in Bernstein’s Strategic Decisions Conference on May 28, which could give investors updated strategic and pipeline commentary, but the event itself is not a major near-term catalyst. Article Title
• Neutral Sentiment: Healthcare stocks were broadly stronger late Monday, which may have helped support LLY alongside the sector, but this looks like a market-wide move rather than a company-specific driver. Article Title
• Negative Sentiment: The Supreme Court’s refusal to hear Lilly’s challenge keeps a Medicaid fraud verdict alive, reinforcing litigation risk and potentially raising concerns about future government-rebate disputes and legal expenses. Article Title
• Negative Sentiment: Competition in obesity treatment remains intense, with Citi data suggesting Novo Nordisk’s Wegovy pill still has a strong prescription lead over Lilly’s rival programs, which could temper near-term excitement around Lilly’s market share gains. Article Title

Wall Street Analyst Weigh In

LLY has been the subject of a number of analyst reports. Loop Capital set a $1,200.00 price target on Eli Lilly and Company in a research note on Tuesday, February 10th. Guggenheim reissued a "buy" rating and issued a $1,183.00 price target on shares of Eli Lilly and Company in a research report on Tuesday, May 5th. Wall Street Zen raised Eli Lilly and Company from a "buy" rating to a "strong-buy" rating in a research report on Saturday, May 2nd. CICC Research increased their price target on Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the company a "neutral" rating in a research report on Wednesday, February 11th. Finally, Weiss Ratings raised Eli Lilly and Company from a "buy (b-)" rating to a "buy (b)" rating in a research report on Monday, May 4th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $1,218.33.

Eli Lilly and Company Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.